A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest
safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET)
XL184 in combination with the EGFR inhibitor erlotinib administered to adults with
Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the
objective response rate of daily oral administration of XL184 with or without erlotinib in
subjects with NSCLC who have progressed after responding to treatment with erlotinib.